In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers. When Elon Musk was at Davos last week, an interviewer asked him if he thought aging ...

As global energy demand surges—driven by AI-hungry data centers, advanced manufacturing, and electrified transportation—researchers at the National Renewable Energy Laboratory have unveiled a ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the “recipe” for the transformation. Researchers at Lund University have now created ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a ...

This is read by an automated voice. Please report any issues or inconsistencies here. Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and ...

A new paper in the journal Nature reveals an astonishing—and frankly unsettling—feature of some cancer cells: the ability to physically inject mitochondria into their neighboring cells. These ...

Cancer immunotherapy has advanced the field of medicine and cancer care. Specifically, immunotherapy refers to the targeted treatment of the immune system. Over the last few decades, immunotherapy has ...

Anza anticipates additional adjustments in the coming weeks as manufacturers finalise their FEOC and ITC strategies. Chart: Anza. Despite trade policy uncertainty, the price of solar modules in the US ...

The Defense Department is asking Congress for permission to redirect $5.4 billion in previously approved money to other programs—including an effort to speed up the delivery of two Air Force One ...

PV module prices have fallen by around 5% to 8% across all technology classes in recent weeks. says Martin Schachinger, the founder of pvXchange.com. This means that prices are moving strongly back ...

Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million series B fundraising round. The round was led by Kleiner Perkins alongside ...